Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology (OLYMPE)

Astellas

Status: Completed

Conditions: Haemopathy; Antifungal Prophylaxis

Treatments: Drug: Micafungin

Study type: Observational

Funder types: Industry

Identifiers

NCT02127788

FR-MYC-NI-003

Details and patient eligibility

About

The purpose of this observational study is to describe the actual conditions of prescription of micafungin in antifungal prophylaxis in French haematological and onco-haematological units. The efficacy and the safety outcomes will be described.

Enrollment: 150 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patient with haemopathy or paediatric patients with haemopathy or solid tumor.
• Patient hospitalized in haematology, onco-haematology or onco-paediatrics unit.
• Patient initiating antifungal prophylaxis with micafungin.

Exclusion criteria

• Patient presenting documented fungal infection.
• Patient already included in a biomedical study impacting the care management of invasive fungal infection at the time of inclusion.

Trial design

150 participants in 1 patient group

Micafungin

Description:

Patients affected with haemopathy (or affected with solid tumor for paediatric patients) under antifungal prophylaxis with micafungin.

Treatment:

Drug: Micafungin